United States - English - NLM (National Library of Medicine)

spectrum laboratory products, inc. - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) -

United States - English - NLM (National Library of Medicine)

vet one - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 1 g in 3.027 g - actions and uses: kuzell (1,2,3), payne (4), flemming (5) and denko (6), demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis and various other rheumatoid diseases in man.  anti-inflammatory activity has been well established by fabre (7), domenjoz (8), wilhelmi (9), and yourish (10). lieberman (11) reported on the effective use of phenylbutazone in the treatment of conditions of the musculoskeletal system in dogs, including posterior paralysis associated with intervertebral disc syndrome, fractures, arthritis and injuries to the limbs and joints.  joshua (12) observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs.  ogilvie and sutter (13) reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism and other conditions associated with lameness and musculoskeletal weakness.  camberos (14) reported favorable results with pheny

United States - English - NLM (National Library of Medicine)

clipper distributing company llc - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses. in the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently. use with caution in patients who have a history of drug allergy.

United States - English - NLM (National Library of Medicine)

abbvil chemical llc - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 0.99 kg in 1 kg

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 25 kg in 25 kg

United States - English - NLM (National Library of Medicine)

vetoquinol usa, inc. - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - indications: for the relief of inflammatory conditions associated with the musculoskeletal system in horses. contraindications: use with caution in patients who have a history of drug allergy.

United States - English - NLM (National Library of Medicine)

butler animal health supply - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 200 mg in 1 ml - for relief of inflammatory conditions associated with the musculoskeletal system in horses. treated animals should not be slaughtered for food purposes. parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. use with caution in patients who have a history of drug allergy. for relief of inflammatory conditions associated with the musculoskeletal system in horses. intravenous dosage (not subcutaneous or intramuscular use) : horses : 1 to 2 g per 1,000 lb body weight (5 to 10 ml/1,000 lb) daily. not for use in horses intended for food. see package outsert for additional information. each ml contains: phenylbutazone ............................. 200 mg benzyl alcohol preservative .........10.45 mg sodium hydroxide to adjust ph to 9.5 to 10.0 water for injection ...............................q.s. store in a refrigerator between 2o c and 8o c (36o f and 46o f). take time observe label directions

United States - English - NLM (National Library of Medicine)

clipper distributing company, llc - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 200 mg in 1 ml - for relief of inflammatory conditions associated with the musculoskeletal system in horses. treated animals should not be slaughtered for food purposes. parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. use with caution in patients who have a history of drug allergy. for relief of inflammatory conditions associated with the musculoskeletal system in horses. intravenous dosage (not subcutaneous or intramuscular use) : horses : 1 to 2 g per 1,000 lb body weight (5 to 10 ml/1,000 lb) daily. not for use in horses intended for food. see package outsert for additional information. anada 200-371, approved by fda each ml contains: phenylbutazone ............................. 200 mg benzyl alcohol preservative .........10.45 mg sodium hydroxide to adjust ph to 9.5 to 10.0 water for injection ...............................q.s.

United States - English - NLM (National Library of Medicine)

covetrus north america - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - for relief of inflammatory conditions associated with the musculoskeletal system in horses. treated animals should not be slaughtered for food purposes. parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. use with caution in patients who have a history of drug allergy. for relief of inflammatory conditions associated with the musculoskeletal system in horses. intravenous dosage (not subcutaneous or intramuscular use) : horses : 1 to 2 g per 1,000 lb body weight (5 to 10 ml/1,000 lb) daily. not for use in horses intended for food. see package outsert for additional information. store in a refrigerator between 2o c and 8o c (36o f and 46o f).

United States - English - NLM (National Library of Medicine)

bimeda, inc. - phenylbutazone (unii: gn5p7k3t8s) (phenylbutazone - unii:gn5p7k3t8s) - phenylbutazone 1 g in 3.027 g - actions and uses: kuzell (1,2,3), payne(4), flemming(5) and denko(6), demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis and various other rheumatoid diseases in man. anti-inflammatory activity has been well established by fabre(7), domenjoz(8), wilhelmi(9), and yourish(10). lieberman(11) reported on the effective use of phenylbutazone in the treatment of conditions of the musculoskeletal system in dogs, including posterior paralysis associated with intervertebral disc syndrome, fractures, arthritis and injuries to the limbs and joints. joshua(12) observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. ogilvie and sutter(13) reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism and other conditions associated with lameness and musculoskeletal weakness. camberos(14) reported faborable results with phenylbutazone folow